Thermo Fisher Scientific (TMO) – Investment Analysts’ Weekly Ratings Updates

Thermo Fisher Scientific (NYSE: TMO) has recently received a number of price target changes and ratings updates:

• 9/11/2025 – Thermo Fisher Scientific was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $550.00 price target on the stock, up previously from $490.00.
• 9/7/2025 – Thermo Fisher Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 9/2/2025 – Thermo Fisher Scientific was given a new $561.00 price target on by analysts at Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 8/30/2025 – Thermo Fisher Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 8/18/2025 – Thermo Fisher Scientific is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 8/10/2025 – Thermo Fisher Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 8/2/2025 – Thermo Fisher Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 7/24/2025 – Thermo Fisher Scientific had its price target lowered by analysts at Wells Fargo & Company from $570.00 to $565.00. They now have an “overweight” rating on the stock.
• 7/24/2025 – Thermo Fisher Scientific had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $535.00 price target on the stock, up previously from $525.00.
• 7/24/2025 – Thermo Fisher Scientific had its price target raised by analysts at Robert W. Baird from $553.00 to $567.00. They now have an “outperform” rating on the stock.
• 7/24/2025 – Thermo Fisher Scientific had its price target raised by analysts at UBS Group AG from $460.00 to $500.00. They now have a “neutral” rating on the stock.
• 7/24/2025 – Thermo Fisher Scientific was downgraded by analysts at Hsbc Global Res from a “strong-buy” rating to a “hold” rating.
• 7/24/2025 – Thermo Fisher Scientific had its “hold” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $510.00 price target on the stock.
• 7/24/2025 – Thermo Fisher Scientific had its price target raised by analysts at Barclays PLC from $450.00 to $490.00. They now have an “equal weight” rating on the stock.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.